Effect of mirtazapine for benzodiazepines use compared with selective serotonin reuptake inhibitors in patients with major depressive disorder: A multicenter, open-label, randomized, controlled trial

被引：0

作者：

Hashimoto, T. ^{[1
]}

Shiina, A. ^{[2
]}

Hasegawa, T. ^{[2
]}

Kimura, H. ^{[3
]}

Niitsu, T. ^{[1
]}

Tachibana, M. ^{[4
]}

Muneoka, K. ^{[5
]}

Matsuki, S. ^{[1
]}

Nakazato, M. ^{[1
]}

Shiraishi, T. ^{[1
]}

Iyo, M. ^{[1
]}

机构：

[1] Chiba Univ, Chiba, Japan

[2] Chiba Univ, Kokoronokenko Clin Tsudanuma, Chiba, Japan

[3] Chiba Univ, Kokoronokaze Clin, Chiba, Japan

[4] Fujita Hosp, Chiba, Japan

[5] Kimura Hosp, Chiba, Japan

来源：

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2014年 / 17卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：56 / 56

页数：1

共 50 条

[31] CLINICAL OUTCOMES OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER TREATED WITH EITHER DULOXETINE OR SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN MEXICO
Hong, J.
Novick, D.
Montgomery, W.
Duenas, H.
Peng, X.
Kadziola, Z.
Haro, J. M.
VALUE IN HEALTH, 2013, 16 (07) : A694 - A694
[32] Study of effects of selective serotonin reuptake inhibitors on stages of sexual function in Iranian patients with major depressive disorder
Safa, Mitra
Sadr, Saeid
Talischi, Firouzeh
Boroujerdi, Fatemeh Ghasem
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2013, 3 (06) : 306 - 313
[33] Dual Roles for the TSPYL Family in Mediating Serotonin Transport and the Metabolism of Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder
Qin, Sisi
Eugene, Andy R.
Liu, Duan
Zhang, Lingxin
Neavin, Drew
Biernacka, Joanna M.
Yu, Jia
Weinshilboumi, Richard M.
Wang, Liewei
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 (03) : 662 - 670
[34] Efficacy of Buspirone Augmentation of Escitalopram in Patients with Major Depressive Disorder with and without Atypical Features: A Randomized, 8 Week, Multicenter, Open-Label Clinical Trial
Shin, Cheolmin
Ko, Young-Hoon
Shim, Se-Hoon
Kim, Ji Sun
Na, Kyoung-Sae
Hahn, Sang-Woo
Lee, Seung-Hwan
PSYCHIATRY INVESTIGATION, 2020, 17 (08) : 796 - 803
[35] A randomized open-label trial of paroxetine versus paroxetine plus sulpiride in the treatment of major depressive disorder
Uchida, H
Takeuchi, H
Nomura, K
Suzuki, T
Watanabe, K
Kashima, H
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2005, 20 (03) : A16 - A16
[36] Effect of reboxetine on major depressive disorder in breast cancer patients: An open-label study
Grassi, L
Biancosino, B
Marmai, L
Righi, R
JOURNAL OF CLINICAL PSYCHIATRY, 2004, 65 (04) : 515 - 520
[37] Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial
Kim, J. E.
Yoon, S. J.
Kim, J.
Jung, J. Y.
Jeong, H. S.
Cho, H. B.
Shin, E.
Lyoo, I. K.
Kim, T. S.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2011, 65 (03) : 323 - 329
[38] EFFICACY OF VENLAFAXINE COMPARED WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRI) IN SEVERE MAJOR DEPRESSIVE DISORDER (MDD): A RETROSPECTIVE POOLED ANALYSIS
Chatterjee, A.
Fayyad, R.
EUROPEAN PSYCHIATRY, 2012, 27
[39] Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: Analysis of patients beginning adjunctive treatment in a 52-week, open-label study
Clayton A.H.
Baker R.A.
Sheehan J.J.
Cain Z.J.
Forbes R.A.
Marler S.V.
Marcus R.
Berman R.M.
Thase M.E.
BMC Research Notes, 7 (1)
[40] Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials
Huang, Kai-Lin
Lui, Wan-Chen
Wang, Ying-Yue
Hu, Gwo-Chi
Lui, Chien-Hung
Lee, Wei-Ying
Hsu, Chien-Chi
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2014, 48 (07): : 663 - 671

← 1 2 3 4 5 →